Literature DB >> 1700245

Fludarabine for prolymphocytic leukaemia and risk of interstitial pneumonitis.

F Cervantes, C Salgado, E Montserrat, C Rozman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 1700245     DOI： 10.1016/0140-6736(90)92606-i

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

1.  Lysis pneumonopathy associated with the use of fludarabine phosphate.

Authors:  J J Crowley; L Knight; N Charan
Journal:  West J Med       Date:  1994-12

Review 2.  Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies.

Authors:  J C Adkins; D H Peters; A Markham
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

Review 3.  Management of chronic lymphocytic leukaemia.

Authors:  N Kalil; B D Cheson
Journal:  Drugs Aging       Date:  2000-01       Impact factor: 3.923

Review 4.  Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy.

Authors:  S R Ross; D McTavish; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

5.  Corticosteroid-responsive pulmonary toxicity associated with fludarabine monophosphate: a case report.

Authors:  Milda Rudzianskiene; Rasa Griniute; Elona Juozaityte; Arturas Inciura; Viktoras Rudzianskas; Greta Emilia Kiavialaitis
Journal:  Turk J Haematol       Date:  2012-12-05       Impact factor: 1.831
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.